Acute arrhythmogenicity of doxorubicin administration
Open Access
- 15 September 1987
- Vol. 60 (6) , 1213-1218
- https://doi.org/10.1002/1097-0142(19870915)60:6<1213::aid-cncr2820600609>3.0.co;2-v
Abstract
The magnitude of acute arrhythmogenicity of doxorubicin administration has not been characterized. In this study the type and frequency of cardiac arrhythmia is determined in the first hour and first 24 hours following doxorubicin given as a 10‐minute infusion. Twenty‐nine patients with diverse malignancies were studied with Holter monitors on 33 postdoxorubicin days. Control recordings were made on days remote from doxorubicin treatment. The frequency of arrhythmia that could be attributed to doxorubicin was low: 3% of studies in the first hour postinfusion and 24% of studies in 1 to 24 hours postinfusion. The most commonly seen arrhythmia was an increased frequency of ventricular premature beats. Arrhythmia following doxorubicin infusion is rare in the first hour and more common in the remainder of the first 24 hours postinfusion. There are no acute or long‐term adverse consequences related to the appearance of arrhythmia due to doxorubicin.This publication has 16 references indexed in Scilit:
- The effects of adriamycin on normal and ouabain-toxic canine Purkinje and ventricular muscle fibers.Circulation Research, 1983
- Sudden death during doxorubicin administrationCancer, 1979
- Electrocardiographic changes following adriamycin treatmentMedical and Pediatric Oncology, 1978
- Adriamycin Cardiotoxicity in ManAnnals of Internal Medicine, 1974
- A clinicopathologic analysis of adriamycin cardiotoxicityCancer, 1973
- Phase II evaluation of adriamycin in human neoplasiaCancer, 1973
- Adriamycin—an antitumor antibiotic in the treatment of neoplastic diseasesCancer, 1973
- Clinical Trials with Adriamycin. Results of Three-Years StudyPublished by Springer Nature ,1972
- Clinical trials with adriamycinCancer, 1971
- Therapeutic effect and toxicity of adriamycin in patients with neoplastic diseaseCancer, 1971